William R. Shepard, a director at CME Group Inc. (NASDAQ:CME), has substantially expanded his equity position in the exchange operator through a series of recent transactions. The timing of these acquisitions is particularly notable given the current market context. On June 25, 2026, Mr. Shepard acquired shares valued at $78,186. The per-share price for these transactions was recorded at $230.57. This purchase activity stands in contrast to the recent performance of CME Group's stock, which is currently trading at $218.56. This price point sits near the company's 52-week low of $220.73 and reflects a decline of nearly 10% over the preceding week. According to analysis from InvestingPro, the current valuation suggests the stock may be undervalued, placing CME Group on lists of companies featuring attractive valuation metrics.
The acquisitions by Mr. Shepard were executed through a broker-administered dividend reinvestment plan. The structure of these purchases involved both direct and indirect holdings. Specifically, Mr. Shepard directly acquired 14.318 shares. Concurrently, he indirectly acquired 324.782 shares through a trust. Both sets of shares were obtained at the same price of $230.57 per share. Following these transactions, Mr. Shepard's indirect ownership in CME Group Inc. through the trust stands at 260,442.322 shares of Common Stock Class A. His direct ownership is recorded at 3,620.768 shares.
In addition to the market-based purchases, Mr. Shepard also received common stock as part of his compensation package. On the same date, June 25, 2026, he acquired 645 shares of Common Stock Class A at $225.00 per share. These shares represent a grant of fully vested shares under the company’s annual equity compensation program for non-employee directors. Furthermore, he acquired an additional 422 shares of Common Stock Class A, also at $225.00 per share. These specific shares were issued at his election in lieu of a portion of his annual cash retainer for serving on the Board of Directors. The total value of these compensation-related acquisitions was $240,075.
CME Group, which holds a market capitalization of $79.72 billion, offers shareholders a dividend yield of 2.35%. An InvestingPro tip highlights that the company has maintained dividend payments for 24 consecutive years. For deeper insights into CME’s valuation and growth prospects, investors can access the comprehensive Pro Research Report, available for this and 1,400+ other US equities.
Market data indicates that CME Group stock closed at 218.56 USD, reflecting a decline of 2.44 or 1.10%. After hours trading showed a slight recovery, with the stock at 219.68 USD, up 1.10 or 0.50%. The trading activity is monitored across various timeframes, including 1D, 1W, 1M, 6M, 1Y, 5Y, and Max.
In other recent developments, CME Group faced trading disruptions due to disconnects, as reported by Bloomberg News. The exchange operator’s support team is currently investigating the incident. Additionally, Keefe, Bruyette & Woods upgraded CME Group’s stock rating to Outperform, maintaining a price target of $305. The firm cited an attractive risk/reward opportunity after a recent decline in stock value. Meanwhile, Piper Sandler reiterated an Overweight rating with a $320 price target following the announcement of a leadership change. CEO Terry Duffy will transition to Executive Chairman in March 2027, with President and CFO Lynne Fitzpatrick stepping in as the new CEO. Duffy’s tenure saw significant growth, with the company’s market capitalization exceeding $95 billion. Piper Sandler also reiterated an Overweight rating with a $329 price target, noting concerns about the impact of Bitcoin perpetuals approved by the CFTC for Kalshi on CME’s futures complex.